Background
High-volume (HV) center surgery and gynecologic oncology care are associated with improved outcomes for women with uterine cancer. Referral patterns, from biopsy through to chemotherapy, may have patients interacting with HV centers for all, a portion, or none of their care. The relative frequency, the underlying factors that contribute to referral, and the potential impact of these referral patterns on treatment outcomes are unknown.
Objective
To analyze the referral patterns and subsequent impact of care sites on treatment for women with high and low risk uterine cancer.
Methods
This is a population-based retrospective cohort study of uterine cancer cases from 2004–09 in North Carolina. Using state cancer registry files linked to Medicare, Medicaid, and private payer insurance claims, we analyzed referral and treatment patterns by annual surgical volume (High ≥ 12/year). We examined clinical and demographic factors associated with referral and used modified Poisson regression to evaluate risk of referral, lymphadenectomy and chemotherapy. Stratified Kaplan Meier plots and Cox proportional hazard models were used to examine survival.
Results
A total of 2,053 women were analyzed, including 34% (n=677) with Grade 3 histology. Of 1,630 (80%) of women with pre-operative biopsies, referral patterns (Biopsy to Surgery) were: LV to HV (n=652, 40%), followed by HV to HV (n=605, 37%), then LV to LV (n=318, 20%), and the rare HV to LV (n=50, 3%). Women retained in Low-Volume centers after biopsy were older, were less likely to have private insurance, and had more comorbidities. High-risk histology (aRR 1.14, 95%CI: 1.04–1.25) was positively associated with referral, while Medicaid insurance was negatively associated with referral (aRR 0.64, 95%CI: 0.42–0.96). Most women (74%, n=1,557) had surgery at HV centers. Lymphadenectomy was less likely at Low-Volume (LV) centers (aRR 0.71, 95%CI: 0.64–0.77). Similarly, for high-risk patients, the relationship between LV center surgery and subsequent chemotherapy was aRR 0.71 (95%CI: 0.48–1.02).
Of 290 women who received chemotherapy, the referral patterns (Surgery to Chemotherapy) were: HV- All (HV to HV), HV-Hybrid (HV to LV, or LV to HV), and HV-None (LV to LV). 36% (n=104/290) received chemotherapy at a LV center, the majority (68%, n=71/104) of whom were referred from out of HV centers after surgery. Crude, unadjusted mortality risk of chemotherapy recipients differed by referral pattern (Surgery to Chemotherapy): HV-All patients (HR 1.0, referent), followed by HV-Hybrid (HR 1.33, 95%CI: 0.93–1.91) then HV-None patients (RR 1.95, 95%CI:1.24–3.08).
Conclusion
Most women with uterine cancer treated at High-Volume centers arrive through referral, which is affected by age and type of insurance, in addition to histology. For high-risk women who require chemotherapy, survival may be related to the extent of treatment received at High-Volume centers.